JPWO2020232019A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020232019A5 JPWO2020232019A5 JP2021563296A JP2021563296A JPWO2020232019A5 JP WO2020232019 A5 JPWO2020232019 A5 JP WO2020232019A5 JP 2021563296 A JP2021563296 A JP 2021563296A JP 2021563296 A JP2021563296 A JP 2021563296A JP WO2020232019 A5 JPWO2020232019 A5 JP WO2020232019A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962847068P | 2019-05-13 | 2019-05-13 | |
US62/847,068 | 2019-05-13 | ||
PCT/US2020/032515 WO2020232019A1 (en) | 2019-05-13 | 2020-05-12 | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022532490A JP2022532490A (ja) | 2022-07-15 |
JPWO2020232019A5 true JPWO2020232019A5 (hr) | 2023-10-05 |
Family
ID=71069936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021563296A Pending JP2022532490A (ja) | 2019-05-13 | 2020-05-12 | 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220249659A1 (hr) |
EP (1) | EP3969040A1 (hr) |
JP (1) | JP2022532490A (hr) |
KR (1) | KR20220007593A (hr) |
CN (1) | CN113825527A (hr) |
AU (1) | AU2020276242A1 (hr) |
BR (1) | BR112021021713A2 (hr) |
CA (1) | CA3136568A1 (hr) |
CL (1) | CL2021002966A1 (hr) |
EA (1) | EA202192528A1 (hr) |
IL (1) | IL287728A (hr) |
MA (1) | MA55965A (hr) |
MX (1) | MX2021013815A (hr) |
SG (1) | SG11202111262XA (hr) |
WO (1) | WO2020232019A1 (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023500337A (ja) * | 2019-11-04 | 2023-01-05 | イノビオ ファーマシューティカルズ,インコーポレイティド | 脳がんを治療するための併用療法 |
EP4377351A1 (en) * | 2021-07-28 | 2024-06-05 | F. Hoffmann-La Roche AG | Methods and compositions for treating cancer |
CN115845052B (zh) * | 2022-12-28 | 2023-12-29 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗结肠癌中的应用 |
CN115869399B (zh) * | 2022-12-28 | 2024-01-12 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
KR100257466B1 (ko) | 1994-05-06 | 2000-07-01 | 레지날드 쇼트버그 에스. 안토니우스-소도 | Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체 |
US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
DE69624824T2 (de) | 1995-07-21 | 2003-09-11 | Applied Research Systems Ars Holding N.V., Curacao | Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein |
EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス, インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
EP1897548B2 (en) | 2003-02-28 | 2024-05-22 | The Johns Hopkins University | T cell regulation |
AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
SI2970464T1 (sl) | 2013-03-15 | 2020-08-31 | Glaxosmithkline Intellectual Propety Development Limited | Anti-LAG-3 vezavni proteini |
EP3508502B1 (en) * | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
DK3254110T3 (da) | 2015-02-03 | 2020-05-18 | Ventana Med Syst Inc | Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1) |
US20180155429A1 (en) | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
KR20180042412A (ko) | 2015-09-02 | 2018-04-25 | 이뮤텝 에스.에이.에스. | 항-lag-3 항체 |
TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
TWI755395B (zh) * | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
MA55697A (fr) * | 2016-05-18 | 2022-02-23 | Boehringer Ingelheim Int | Molécules d'anticorps pour le traitement du cancer |
CN110023337B (zh) | 2016-10-11 | 2024-01-05 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
BR112019006876A2 (pt) | 2016-10-13 | 2019-06-25 | Symphogen As | anticorpos e composições anti-lag-3 |
CN110234661B (zh) | 2016-12-01 | 2024-03-29 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的抗-pd-l1抗体 |
SG11201907208XA (en) | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
JP2020513009A (ja) * | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブSymphogen A/S | Pd−1、tim−3、およびlag−3を標的とする併用治療 |
-
2020
- 2020-05-12 MA MA055965A patent/MA55965A/fr unknown
- 2020-05-12 CA CA3136568A patent/CA3136568A1/en active Pending
- 2020-05-12 MX MX2021013815A patent/MX2021013815A/es unknown
- 2020-05-12 AU AU2020276242A patent/AU2020276242A1/en active Pending
- 2020-05-12 EP EP20731629.0A patent/EP3969040A1/en active Pending
- 2020-05-12 WO PCT/US2020/032515 patent/WO2020232019A1/en unknown
- 2020-05-12 JP JP2021563296A patent/JP2022532490A/ja active Pending
- 2020-05-12 BR BR112021021713A patent/BR112021021713A2/pt unknown
- 2020-05-12 EA EA202192528A patent/EA202192528A1/ru unknown
- 2020-05-12 KR KR1020217034542A patent/KR20220007593A/ko unknown
- 2020-05-12 US US17/611,073 patent/US20220249659A1/en active Pending
- 2020-05-12 CN CN202080035740.2A patent/CN113825527A/zh active Pending
- 2020-05-12 SG SG11202111262XA patent/SG11202111262XA/en unknown
-
2021
- 2021-10-31 IL IL287728A patent/IL287728A/en unknown
- 2021-11-10 CL CL2021002966A patent/CL2021002966A1/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI786044B (zh) | 藉由投予pd-1抑制劑治療皮膚癌之方法 | |
JP7126941B2 (ja) | がんを治療するための抗pd-1抗体と二重特異性抗cd20/抗cd3抗体の組合せ | |
JP2022050618A5 (hr) | ||
ES2855798T3 (es) | Método de tratamiento del cáncer usando un inhibidor de puntos de control inmunitario; anticuerpo que se une al receptor de muerte programada 1 (pd-1) o al ligando de muerte programada 1 (pd-l1) | |
RU2695332C2 (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
JP2022031638A (ja) | 放射線療法と併用されるpd-1およびpd-l1に対する拮抗薬を用いたがんの治療法 | |
JP2019515008A5 (hr) | ||
TW201545759A (zh) | 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體 | |
JP2020508317A5 (hr) | ||
IL308805A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
US20220249659A1 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
CN117603360A (zh) | 用于治疗癌症的多特异性抗体 | |
US20210277135A1 (en) | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor | |
JPWO2019246356A5 (hr) | ||
JPWO2020232019A5 (hr) | ||
JP2023011902A (ja) | Pd-1阻害剤を投与することにより子宮頸がんを処置する方法 | |
RU2021128914A (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
RU2024117128A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ПОСРЕДСТВОМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К CD3 x MUC16 И АНТИТЕЛ К CTLA-4 | |
Pan et al. | PS1211 CD22 CAR T-CELL THERAPY IN 34 REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | |
CA3170733A1 (en) | Methods of treating lung cancer by administering a pd-1 inhibitor | |
CN116887863A (zh) | 通过施用pd-1抑制剂治疗肺癌的方法 |